Chronic active hepatitis: immunopathogenesis and immunotherapy.
D000914:Antibodies, Viral / Q000032:analysis; D000961:Antilymphocyte Serum; D001327:Autoimmune Diseases; D001379:Azathioprine / Q000627:therapeutic use; D002353:Carrier State / Q000276:immunology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006525:Hepatitis, Viral, Human / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D006649:Histocompatibility Antigens / Q000032:analysis; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008099:Liver / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008565:Membrane Proteins / Q000276:immunology; D010396:Penicillamine / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D014165:Transfer Factor / Q000627:therapeutic use; D014740:Vidarabine / Q000627:therapeutic use
D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D006514:Hepatitis B Surface Antigens; D006649:Histocompatibility Antigens; D008565:Membrane Proteins; D014165:Transfer Factor; D003520:Cyclophosphamide; D007372:Interferons; D011239:Prednisolone; D014740:Vidarabine; D010396:Penicillamine; D001379:Azathioprine; D011241:Prednisone